EUVIMEDEUVIMED entdecken
Crossref

Gilteritinib (Xospata)

CDA-AMC

Canadian Journal of Health Technologies · 29.10.2026 · 6 (10)

DOI: 10.51731/cjht.2026.1555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Journal of Health Technologies, online erschienen am 29.10.2026. Verfasst von CDA-AMC.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses gilteritinib (Xospata), 40 mg, tablet, oral. Indication: The treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation.

Zitieren

APA

CDA-AMC (2026). Gilteritinib (Xospata). Canadian Journal of Health Technologies, 6(10). https://doi.org/10.51731/cjht.2026.1555

Vancouver

CDA-AMC. Gilteritinib (Xospata). Canadian Journal of Health Technologies. 2026;6(10). doi:10.51731/cjht.2026.1555

BibTeX
@article{CDAAMC2026,
  author = {CDA-AMC},
  title = {Gilteritinib (Xospata)},
  journal = {Canadian Journal of Health Technologies},
  year = {2026},
  volume = {6},
  number = {10},
  doi = {10.51731/cjht.2026.1555}
}
Kostenlos starten →